Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

3 Major Regional Banks to Bet on Amid Favorable Industry Tailwinds
3 Major Regional Banks to Bet on Amid Favorable Industry Tailwinds
The Zacks Major Regional Banks’ asset quality is expected to remain weak in the near term due to the challenging operating backdrop. Yet, as the Federal Reserve lowers interest rates, industry
Abercrombie & Fitch (ANF) Surpasses Q4 Earnings and Revenue Estimates
Abercrombie & Fitch (ANF) Surpasses Q4 Earnings and Revenue Estimates

Abercrombie & Fitch (ANF) came out with quarterly earnings of $3.68 per share, beating the Zacks Consensus Estimate of $3.56 per share. This compares to earnings of $3.57 per share a year ago. These

Advanced Flower Capital Inc. (AFCG) Reports Q4 Loss, Lags Revenue Estimates
Advanced Flower Capital Inc. (AFCG) Reports Q4 Loss, Lags Revenue Estimates

Advanced Flower Capital Inc. (AFCG) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.29 per share a year ago

3 Top-Ranked Vanguard Mutual Funds You Should Consider Buying
3 Top-Ranked Vanguard Mutual Funds You Should Consider Buying

Vanguard, one of the world’s largest asset management corporations, was founded by John C. Bogle on May 1, 1975. Headquartered in Valley Forge, PN, the company had $11 trillion in assets under

Holley Inc. (HLLY) Misses Q4 Earnings Estimates
Holley Inc. (HLLY) Misses Q4 Earnings Estimates

Holley Inc. (HLLY) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.11 per share a year ago. These

Daktronics (DAKT) Misses Q3 Earnings Estimates
Daktronics (DAKT) Misses Q3 Earnings Estimates

Daktronics (DAKT) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.01 per share a year ago. These figures

New Strong Sell Stocks for March 4th
New Strong Sell Stocks for March 4th

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:

BKV Corporation BKV is an energy company, which produce natural gas from its owned and operated upstream businesses. The

JD Gears Up to Report Q4 Earnings: What's in Store for the Stock?
JD Gears Up to Report Q4 Earnings: What's in Store for the Stock?

JD.com JD is scheduled to release fourth-quarter 2025 results on March 5.The Zacks Consensus Estimate for JD’s fourth-quarter revenues is pegged at $50.22 billion, indicating an increase of 5.64% on

Here's How Much a $1000 Investment in HubSpot Made 10 Years Ago Would Be Worth Today
Here's How Much a $1000 Investment in HubSpot Made 10 Years Ago Would Be Worth Today

For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and

Here's How Much You'd Have If You Invested $1000 in Fair Isaac a Decade Ago
Here's How Much You'd Have If You Invested $1000 in Fair Isaac a Decade Ago

For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and

If You Invested $1000 in ATI a Decade Ago, This is How Much It'd Be Worth Now
If You Invested $1000 in ATI a Decade Ago, This is How Much It'd Be Worth Now

How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across

Will Petrobras Pull Off Q4 Earnings Beat on Strong Production?
Will Petrobras Pull Off Q4 Earnings Beat on Strong Production?

Petroleo Brasileiro S.A., or Petrobras PBR, is set to release fourth-quarter 2025 results on March 5. The Zacks Consensus Estimate for the to-be-reported quarter is a profit of 57 cents per share on

Chewy Expands Pet Health Platform: Is CHWY a Long-Term Play?
Chewy Expands Pet Health Platform: Is CHWY a Long-Term Play?

Chewy, Inc. CHWY built its brand as a pure-play pet e-commerce platform spanning food, treats, supplies and medications. Now the company is pushing deeper into pet health and services that can lift

Why Home Depot Expects Second Half Comps to Outperform First Half
Why Home Depot Expects Second Half Comps to Outperform First Half

The Home Depot, Inc. HD expects comparable sales growth in fiscal 2026 to be stronger in the second half than in the first half. Management expects comparable sales to be flat to up 2% for the

Dycom Industries (DY) Q4 Earnings and Revenues Surpass Estimates
Dycom Industries (DY) Q4 Earnings and Revenues Surpass Estimates

Dycom Industries (DY) came out with quarterly earnings of $2.03 per share, beating the Zacks Consensus Estimate of $1.91 per share. This compares to earnings of $1.17 per share a year ago. These

EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates
EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates

EyePoint (EYPT) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $0.64 per share a year ago. These figures are

D-Wave Quantum's Q4 Bookings Fall Y/Y: How Does the Year Ahead Look?
D-Wave Quantum's Q4 Bookings Fall Y/Y: How Does the Year Ahead Look?

D-Wave Quantum QBTS reported bookings of $13.4 million in the fourth quarter of 2025, down 27% compared to the prior-year period, which benefited from an eight-figure system sale. On a sequential

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.29 per share a year ago. These

The Real Brokerage Inc. (REAX) Reports Q4 Loss, Beats Revenue Estimates
The Real Brokerage Inc. (REAX) Reports Q4 Loss, Beats Revenue Estimates

The Real Brokerage Inc. (REAX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.03 per share a year ago. These

Is This the Right Time to Hold Labcorp Stock in Your Portfolio?
Is This the Right Time to Hold Labcorp Stock in Your Portfolio?

Labcorp Holdings Inc. LH, or Labcorp, is well-poised for growth in the coming quarters due to its test expansion in strategic high-growth areas, including neurology and autoimmune disease. The

BigBear.ai Stock Is Down Big, But Smart Money Is Quietly Buying
BigBear.ai Stock Is Down Big, But Smart Money Is Quietly Buying

There are reasons why BigBear.ai (NYSE: BBAI) stock struggled to gain traction in 2025, eventually falling to long-term lows, but the story is changing in 2026. Issues keeping analysts and

3 Resilient Sales Growth Stocks for Navigating a Risk-Off Market
3 Resilient Sales Growth Stocks for Navigating a Risk-Off Market

This year started on a weak note. U.S. markets have seen bouts of selling tied to shifting AI expectations and geopolitical tensions, especially Middle East risks and oil-shock fears, prompting

Riskified (RSKD) Q4 Earnings and Revenues Top Estimates
Riskified (RSKD) Q4 Earnings and Revenues Top Estimates

Riskified (RSKD) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.06 per share a year ago. These figures

Bath & Body Works (BBWI) Q4 Earnings and Revenues Surpass Estimates
Bath & Body Works (BBWI) Q4 Earnings and Revenues Surpass Estimates

Bath & Body Works (BBWI) came out with quarterly earnings of $2.05 per share, beating the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $2.09 per share a year ago. These

ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU

Acadia Pharmaceuticals ACAD announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has formally adopted a negative opinion recommending